Developer docs
API playgroundTry for free, no card

Search company profiles

Inocras

Full company profile

uuid0000a8y

Namestring
Inocras
Legal namestring
Inocras Inc.
Websiteurl
inocras.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Inocras is a private bioinformatics-led genomic testing company founded in 2020 and headquartered in San Diego, with operational entities in South Korea (Daejeon) and Hong Kong. The company operates a CAP-accredited, CLIA-certified, and ANAB-accredited laboratory and delivers three whole-genome clinical assays: CancerVision (target-enhanced WGS for solid tumor profiling with paired somatic and germline analysis, 600-gene panel at 500× depth, and 2-week turnaround), MRDVision (whole-genome, tumor-informed ctDNA minimal residual disease detection at LOD95 as low as 1 ppm, integrated with Ultima Genomics' ppmSeq technology), and RareVision (30× germline WGS covering 5,000+ rare diseases per ACMG/ClinGen standards). The platform is supported by a research services business providing WGS/WES/WTS, methylation, single-cell, and spatial transcriptomics to biopharma, biobanks, and health tech clients, with named deployments at Samsung Medical Center, Seoul St. Mary's Hospital, the Broad Institute, and 50+ additional research and biopharma institutions.

Underpinning the clinical and research products is a proprietary AI stack centered on DNAChunker, a learnable adaptive tokenization architecture co-developed with KAIST and accepted at ICML 2026, and a Cancer Foundation Model trained on 2,882 whole genomes. These power variant calling, structural variant and copy number detection, mutational signature analysis, and clinical interpretation across the product family. The company has assembled large harmonized whole-genome data assets (8,000+ TCGA tumor-normal whole genomes with the Broad Institute, 1,364-genome breast cancer cohort published in Nature 2025, 10,000+ research WGS) and announced a planned 100,000-patient cancer genome program for 2026.

Inocras generates revenue through per-test clinical fees for CancerVision, MRDVision, and RareVision (patients pay out-of-pocket in the US as these tests are not currently covered by insurance), recurring MRDVision follow-up tests priced at promotional $1,000/test ($4,000 for four), project-based research sequencing and bioinformatics services to biopharma and biobanks, and managed-services biopharma clinical trial partnerships (e.g., Accent Therapeutics' ATX-295 Phase 1/2 study). The company sells through a direct sales team to hospitals, oncologists, and biopharma, supplemented by a self-serve online provider order portal, a direct-to-consumer patient portal at portal.inocras.com, and reseller channels including NDS Corporation for cloud-based deployment into healthcare institutions. Backers include Samsung Ventures, Asan Foundation, Seoul Clinical Laboratories, Ignite Innovations, DSC Investment, Dunamu & Partners, InterVest, Paratus Investment, and Signite, with cumulative disclosed funding of approximately $52.7M across rounds in 2020, 2021, 2022, 2023, and 2024.

Short descriptiontext

Inocras is a San Diego-based bioinformatics company that delivers AI-powered whole-genome clinical testing for cancer (CancerVision), minimal residual disease (MRDVision), and rare diseases (RareVision), serving patients, oncologists, hospitals, and biopharma sponsors from CAP/CLIA-certified labs in the US and South Korea.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
whole genome sequencing, cancer genomic testing, rare disease diagnostics, minimal residual disease detection, clinical bioinformatics services
Industry6 codes
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code5 codes
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services54151
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code5 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Genomic Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Clinical Genomic Testing Services (CancerVision, MRDVision, RareVision)
TypeTransaction Fee
Description

CAP/CLIA-validated whole-genome diagnostic tests billed to patients (out-of-pocket, not currently covered by US insurance) or ordered by providers via online portal. Pricing per test/service, with 2-week turnaround.

inocras.com
2Research Sequencing & Bioinformatics Services
TypeProfessional Services
Description

End-to-end next-generation sequencing (WGS, WES, WTS, methylation, single cell, spatial transcriptomics) plus custom bioinformatics, interpretation, and report generation sold to biopharma, biobanks, research organizations, and health tech firms. Hourly or project-based expert advisory support also offered.

inocras.com
3Biopharma Partnership / Clinical Trial Support
TypeManaged Services
Description

Co-development and clinical-trial enablement programs (e.g., Accent Therapeutics using CancerVision/MRDVision in Phase 1/2 ATX-295; Samsung Medical Center & Seoul St. Mary's Hospital 1,364-genome breast cancer study) generating project-based and milestone revenue from biopharma sponsors.

the-scientist.com
4MRDVision Follow-up Testing (Recurring)
TypeUsage Based
Description

Follow-up MRDVision tests in 7–14 day turnaround after initial baseline, creating repeat/recurring per-test revenue from biopharma and clinical customers tracking patient MRD status over time.

inocras.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1MRDVision promotional bundle
ModelUnit PricingBilling cadencePay-as-you-go
Notes

4 tests for $4,000 (limited-time promotional pricing for MRDVision)

inocras.com
2Clinical CancerVision / RareVision tests
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Per-test pricing not publicly disclosed; US patients pay out-of-pocket (not covered by insurance). Outside the US, coverage varies by country/insurer.

inocras.com
3Research sequencing + bioinformatics services
ModelOtherBilling cadencePay-as-you-go
Notes

Custom project-based pricing; sequencing-only, bioinformatics-only, and end-to-end packages available; hourly or project-based expert advisory support.

inocras.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 3 records shown
1CancerVision™
Description

Target-enhanced whole-genome sequencing test for solid tumor cancer profiling; paired somatic + germline assay with 99% sensitivity, TMB/MSI/HRD signatures, and clinical trial matching.

inocras.com
+2 more records
Core offering1 text field

Inocras delivers CAP/CLIA-certified whole-genome sequencing clinical diagnostic tests—CancerVision for solid tumor profiling, MRDVision for minimal residual disease detection, and RareVision for rare disease diagnosis—processed in its own San Diego laboratory with a 2-week turnaround. It also offers end-to-end research sequencing and bioinformatics services (WGS, WES, WTS, methylation, single-cell, spatial) and biopharma clinical trial support, all built on a cloud-native AWS HealthOmics platform and proprietary AI including the DNAChunker architecture and Cancer Foundation Model.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Detected 23.6% more rare disease cases vs other genetic testing methods (sensorineural hearing loss cohort)
+6 more records
Product overview1 text field

Inocras delivers a bioinformatics-led whole-genome insights platform organized as a portfolio of three core clinical assays plus research services, all built on shared WGS technology and proprietary AI. The three clinical products are CancerVision (solid tumor profiling), MRDVision (minimal residual disease detection), and RareVision (rare disease diagnosis), each delivered through Inocras's CAP/CLIA-certified laboratory with a 2-week turnaround. MRDVision extends CancerVision by combining it with Ultima Genomics' ppmSeq technology for ultra-sensitive ctDNA monitoring. Underpinning the platform are Inocras's proprietary AI capabilities, notably the DNAChunker learnable tokenization architecture and the Cancer Foundation Model trained on 2,882 whole genomes (developed with KAIST), which together power the variant calling, biomarker prediction, and clinical interpretation pipelines across the product family. End-to-end Research Services (sequencing plus bioinformatics, including NovaSeq X Plus and Ultima UG 100) round out the offering for biopharma, biobanks, and health technology clients.

Product and service4 records
1CancerVision
CategoryCore clinical assay
Description

Target-enhanced whole-genome sequencing test for solid tumor profiling providing 40x tumor / 20x germline coverage with 600+ clinically relevant genes at 500x depth. Delivers 99% sensitivity/positive predictive value (99% SNVs, >98% indels) in a CAP/CLIA-certified assay with 2-week turnaround, including TMB, MSI, HRD, mutational signatures, and clinical trial matching.

2MRDVision
CategoryCore clinical assay
Description

Whole-genome, tumor-informed ctDNA test for minimal residual disease detection with LOD95 as low as 1 ppm. Combines CancerVision with Ultima Genomics' ppmSeq technology for a panel-free whole-genome MRD design with 100–1,000x greater sensitivity than existing MRD approaches and 2-week (7–14 day follow-up) turnaround.

3RareVision
CategoryCore clinical assay
Description

Whole-genome test for rare disease diagnosis covering genes associated with 5,000+ rare diseases at approximately 30x depth. Identifies 23.6% more rare disease cases vs other genetic testing methods and reports positive, inconclusive, and secondary findings per ACMG/ClinGen guidelines, with genetic counseling support.

4Research Sequencing and Bioinformatics Services
CategoryResearch services offering
Description

End-to-end next-generation sequencing (WGS, WES, WTS, methylation, single cell, spatial transcriptomics) plus custom bioinformatics, interpretation, and report generation on Illumina NovaSeq X Plus and Ultima UG 100 platforms, with hourly or project-based expert advisory support. Sold to biopharma, biobanks, research organizations, and health technology companies.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Joint research collaboration with KAIST on DNAChunker, a learnable adaptive tokenization approach for DNA language models. The resulting paper was accepted for publication at ICML 2026. The DNAChunker model achieves state-of-the-art performance matching leading 1.2 billion-parameter DNA language models while using only 172 million parameters (>7x smaller). Previously, Inocras and KAIST also collaborated on the Cancer Foundation Model trained on 2,882 whole genomes (announced Nov 2025).

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Joint research collaboration with the Broad Institute analyzing over 8,000 tumor-normal whole genomes from The Cancer Genome Atlas across more than 30 cancer types, generating more than 250 million harmonized variant calls. Presented at AACR Annual Meeting 2026. The two organizations are jointly introducing the Cancer Genome Nexus initiative to scale the standardized whole-genome framework to larger datasets.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Strategic partnership with NDS Corporation, a South Korean IT services provider focused on healthcare data and cloud solutions, to jointly develop and commercialize cloud-based genomic analysis platforms for healthcare institutions. Combines Inocras's clinical interpretation expertise with NDS's cloud infrastructure on AWS HealthOmics; planned expansion into North America.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-03
Description

Research consortium partner with Inocras and Seoul St. Mary's Hospital that published a comprehensive whole-genome breast cancer study in Nature (2025) analyzing 1,364 genomes and clinical data; identified biomarkers linked to treatment responses and prognosis supporting precision oncology.

5Seoul St. Mary's Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-03
Description

Research consortium partner with Inocras and Samsung Medical Center on the Nature (2025) whole-genome breast cancer study of 1,364 genomes with clinical records.

pharmiweb.com
Strategic tierCoreTypeTechnology or Integration
Description

Technology integration partner: Inocras's MRDVision platform merges its CancerVision whole-genome platform with Ultima Genomics' ppmSeq™ technology to achieve parts-per-million level ctDNA sensitivity. Ultima UG 100 sequencing is also used in Inocras's research sequencing services. Featured as a partner logo on the Inocras website.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as a partner on Inocras's website; relationship provides commercial channel for whole-genome insights into insurance / health offerings.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as a partner on the Inocras website; academic medical center collaboration supporting clinical research and validation.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed as a partner on the Inocras website; consumer/channel partner enabling patient access to Inocras's whole-genome tests.

10Guide Genetics
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Inocras website; collaboration supporting genetic testing / counseling access.

inocras.com
11Seoul Clinical Laboratories (SCL)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as both an investor and partner on the Inocras website; Korean clinical laboratory collaboration supporting sample handling and clinical reach.

inocras.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Listed as a partner on the Inocras website; GTM partner supporting clinical trial enrollment and patient matching services.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Tempus AI
TypeDirect peer
Description

AI-driven precision medicine company offering multi-modal molecular profiling (DNA/RNA), MRD, and biopharma data services. Directly competes with Inocras in AI-led oncology genomics and clinical-trial enablement.

TypeBroad incumbent
Description

Roche subsidiary and pioneer of comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx). Competes head-to-head in solid-tumor profiling with an FDA-approved panel; broader portfolio and deeper payer coverage than Inocras.

TypeDirect peer
Description

Liquid biopsy leader with Guardant360 (tumor profiling) and Reveal MRD. Direct competitor in oncology ctDNA profiling and MRD, where Inocras positions MRDVision with whole-genome panel-free sensitivity.

TypeDirect peer
Description

Oncology and reproductive health testing company whose Signatera tumor-informed MRD is the entrenched standard. Overlaps directly with Inocras's MRDVision in MRD use cases across solid tumors.

TypeDirect peer
Description

Molecular profiling company offering MI Profile (tumor WES/WTS) and Caris Assure MRD. Closely comparable WGS/WES-based profiling and biopharma services model targeting similar oncologists and pharma customers.

TypeDirect peer
Description

Cancer genomics company with NeXT Personal (tumor-informed, whole-genome MRD) and ImmunoID Next platform. Most direct peer to Inocras's WGS-based tumor profiling and MRD strategy.

TypeBroad incumbent
Description

Clinical oncology and rare-disease laboratory offering comprehensive tumor profiling and heme malignancies panels. Competes in the hospital/community oncology channel with broader test menus.

TypeBroad incumbent
Description

Molecular diagnostics company with oncology (Decipher Prostate, Afirma) and recently expanded MRD/biomarker offerings. Overlaps with Inocras in genomic-based clinical decision support for oncologists.

TypeBroad incumbent
Description

Oncology diagnostics leader with Oncotype DX and an emerging MRD franchise (Oncodetect). Comparable in bringing multi-gene and emerging tumor-informed testing into community oncology practice.

TypeEmerging player
Description

Bioinformatics and genomics services company serving hospitals, clinicians, and researchers in India and globally. Comparable as a bioinformatics-led, hospital-anchored clinical genomics provider; partial overlap in clinical reporting and rare-disease use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inocras

Clinical Genomic Diagnosticsinocras.com

Inocras is a San Diego-based bioinformatics company that delivers AI-powered whole-genome clinical testing for cancer (CancerVision), minimal residual disease (MRDVision), and rare diseases (RareVision), serving patients, oncologists, hospitals, and biopharma sponsors from CAP/CLIA-certified labs in the US and South Korea.

What Inocras does

Inocras is a private bioinformatics-led genomic testing company founded in 2020 and headquartered in San Diego, with operational entities in South Korea (Daejeon) and Hong Kong. The company operates a CAP-accredited, CLIA-certified, and ANAB-accredited laboratory and delivers three whole-genome clinical assays: CancerVision (target-enhanced WGS for solid tumor profiling with paired somatic and germline analysis, 600-gene panel at 500× depth, and 2-week turnaround), MRDVision (whole-genome, tumor-informed ctDNA minimal residual disease detection at LOD95 as low as 1 ppm, integrated with Ultima Genomics' ppmSeq technology), and RareVision (30× germline WGS covering 5,000+ rare diseases per ACMG/ClinGen standards). The platform is supported by a research services business providing WGS/WES/WTS, methylation, single-cell, and spatial transcriptomics to biopharma, biobanks, and health tech clients, with named deployments at Samsung Medical Center, Seoul St. Mary's Hospital, the Broad Institute, and 50+ additional research and biopharma institutions.

Underpinning the clinical and research products is a proprietary AI stack centered on DNAChunker, a learnable adaptive tokenization architecture co-developed with KAIST and accepted at ICML 2026, and a Cancer Foundation Model trained on 2,882 whole genomes. These power variant calling, structural variant and copy number detection, mutational signature analysis, and clinical interpretation across the product family. The company has assembled large harmonized whole-genome data assets (8,000+ TCGA tumor-normal whole genomes with the Broad Institute, 1,364-genome breast cancer cohort published in Nature 2025, 10,000+ research WGS) and announced a planned 100,000-patient cancer genome program for 2026.

Inocras generates revenue through per-test clinical fees for CancerVision, MRDVision, and RareVision (patients pay out-of-pocket in the US as these tests are not currently covered by insurance), recurring MRDVision follow-up tests priced at promotional $1,000/test ($4,000 for four), project-based research sequencing and bioinformatics services to biopharma and biobanks, and managed-services biopharma clinical trial partnerships (e.g., Accent Therapeutics' ATX-295 Phase 1/2 study). The company sells through a direct sales team to hospitals, oncologists, and biopharma, supplemented by a self-serve online provider order portal, a direct-to-consumer patient portal at portal.inocras.com, and reseller channels including NDS Corporation for cloud-based deployment into healthcare institutions. Backers include Samsung Ventures, Asan Foundation, Seoul Clinical Laboratories, Ignite Innovations, DSC Investment, Dunamu & Partners, InterVest, Paratus Investment, and Signite, with cumulative disclosed funding of approximately $52.7M across rounds in 2020, 2021, 2022, 2023, and 2024.

Inocras firmographics

Firmographics
Name
Inocras
Legal name
Inocras Inc.
Website
https://inocras.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Inocras is a San Diego-based bioinformatics company that delivers AI-powered whole-genome clinical testing for cancer (CancerVision), minimal residual disease (MRDVision), and rare diseases (RareVision), serving patients, oncologists, hospitals, and biopharma sponsors from CAP/CLIA-certified labs in the US and South Korea.
Ownership category
akta.pro rank

Inocras industry classification

Industry
Product category
Clinical Genomic Diagnostics
NAICS
Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Computer Programming, Data Processing, Etc. (7370), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Whole genome sequencing
  • Cancer genomic testing
  • Rare disease diagnostics
  • Minimal residual disease detection
  • Clinical bioinformatics services

Where Inocras is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Inocras business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Genomic Testing Services (CancerVision, MRDVision, RareVision): CAP/CLIA-validated whole-genome diagnostic tests billed to patients (out-of-pocket, not currently covered by US insurance) or ordered by providers via online portal. Pricing per test/service, with 2-week turnaround.
  2. Research Sequencing & Bioinformatics Services: End-to-end next-generation sequencing (WGS, WES, WTS, methylation, single cell, spatial transcriptomics) plus custom bioinformatics, interpretation, and report generation sold to biopharma, biobanks, research organizations, and health tech firms. Hourly or project-based expert advisory support also offered.
  3. Biopharma Partnership / Clinical Trial Support: Co-development and clinical-trial enablement programs (e.g., Accent Therapeutics using CancerVision/MRDVision in Phase 1/2 ATX-295; Samsung Medical Center & Seoul St. Mary's Hospital 1,364-genome breast cancer study) generating project-based and milestone revenue from biopharma sponsors.
  4. MRDVision Follow-up Testing (Recurring): Follow-up MRDVision tests in 7–14 day turnaround after initial baseline, creating repeat/recurring per-test revenue from biopharma and clinical customers tracking patient MRD status over time.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goMRDVision promotional bundle
Unit PricingPay-as-you-goClinical CancerVision / RareVision tests
OtherPay-as-you-goResearch sequencing + bioinformatics services

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Inocras product offering

Product offering

Core offering

Inocras delivers CAP/CLIA-certified whole-genome sequencing clinical diagnostic tests—CancerVision for solid tumor profiling, MRDVision for minimal residual disease detection, and RareVision for rare disease diagnosis—processed in its own San Diego laboratory with a 2-week turnaround. It also offers end-to-end research sequencing and bioinformatics services (WGS, WES, WTS, methylation, single-cell, spatial) and biopharma clinical trial support, all built on a cloud-native AWS HealthOmics platform and proprietary AI including the DNAChunker architecture and Cancer Foundation Model.

Product overview

Inocras delivers a bioinformatics-led whole-genome insights platform organized as a portfolio of three core clinical assays plus research services, all built on shared WGS technology and proprietary AI. The three clinical products are CancerVision (solid tumor profiling), MRDVision (minimal residual disease detection), and RareVision (rare disease diagnosis), each delivered through Inocras's CAP/CLIA-certified laboratory with a 2-week turnaround. MRDVision extends CancerVision by combining it with Ultima Genomics' ppmSeq technology for ultra-sensitive ctDNA monitoring. Underpinning the platform are Inocras's proprietary AI capabilities, notably the DNAChunker learnable tokenization architecture and the Cancer Foundation Model trained on 2,882 whole genomes (developed with KAIST), which together power the variant calling, biomarker prediction, and clinical interpretation pipelines across the product family. End-to-end Research Services (sequencing plus bioinformatics, including NovaSeq X Plus and Ultima UG 100) round out the offering for biopharma, biobanks, and health technology clients.

Differentiator

Problem solved

Functional benefit

Brands

  • CancerVision™: Target-enhanced whole-genome sequencing test for solid tumor cancer profiling; paired somatic + germline assay with 99% sensitivity, TMB/MSI/HRD signatures, and clinical trial matching.
  • MRDVision™
  • RareVision™

Products and services

  • CancerVision Target-enhanced whole-genome sequencing test for solid tumor profiling providing 40x tumor / 20x germline coverage with 600+ clinically relevant genes at 500x depth. Delivers 99% sensitivity/positive predictive value (99% SNVs, >98% indels) in a CAP/CLIA-certified assay with 2-week turnaround, including TMB, MSI, HRD, mutational signatures, and clinical trial matching.
  • MRDVision Whole-genome, tumor-informed ctDNA test for minimal residual disease detection with LOD95 as low as 1 ppm. Combines CancerVision with Ultima Genomics' ppmSeq technology for a panel-free whole-genome MRD design with 100–1,000x greater sensitivity than existing MRD approaches and 2-week (7–14 day follow-up) turnaround.
  • RareVision Whole-genome test for rare disease diagnosis covering genes associated with 5,000+ rare diseases at approximately 30x depth. Identifies 23.6% more rare disease cases vs other genetic testing methods and reports positive, inconclusive, and secondary findings per ACMG/ClinGen guidelines, with genetic counseling support.
  • Research Sequencing and Bioinformatics Services End-to-end next-generation sequencing (WGS, WES, WTS, methylation, single cell, spatial transcriptomics) plus custom bioinformatics, interpretation, and report generation on Illumina NovaSeq X Plus and Ultima UG 100 platforms, with hourly or project-based expert advisory support. Sold to biopharma, biobanks, research organizations, and health technology companies.

Quantifiable outcome

  • Detected 23.6% more rare disease cases vs other genetic testing methods (sensorineural hearing loss cohort)
  • +6 more outcomes

Companies that use Inocras

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Inocras technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability8 records

Feature6 records

Inocras partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered flagship, core and minor.

  • KAIST (Korea Advanced Institute of Science and Technology)flagshipStrategic or Co-development Partner · 22 June 2026Joint research collaboration with KAIST on DNAChunker, a learnable adaptive tokenization approach for DNA language models. The resulting paper was accepted for publication at ICML 2026. The DNAChunker model achieves state-of-the-art performance matching leading 1.2 billion-parameter DNA language models while using only 172 million parameters (>7x smaller). Previously, Inocras and KAIST also collaborated on the Cancer Foundation Model trained on 2,882 whole genomes (announced Nov 2025).
  • Broad Institute of MIT and HarvardflagshipStrategic or Co-development Partner · 18 March 2026Joint research collaboration with the Broad Institute analyzing over 8,000 tumor-normal whole genomes from The Cancer Genome Atlas across more than 30 cancer types, generating more than 250 million harmonized variant calls. Presented at AACR Annual Meeting 2026. The two organizations are jointly introducing the Cancer Genome Nexus initiative to scale the standardized whole-genome framework to larger datasets.
  • NDS CorporationflagshipStrategic or Co-development Partner · 12 March 2026Strategic partnership with NDS Corporation, a South Korean IT services provider focused on healthcare data and cloud solutions, to jointly develop and commercialize cloud-based genomic analysis platforms for healthcare institutions. Combines Inocras's clinical interpretation expertise with NDS's cloud infrastructure on AWS HealthOmics; planned expansion into North America.
  • Samsung Medical CentercoreStrategic or Co-development Partner · 3 December 2025Research consortium partner with Inocras and Seoul St. Mary's Hospital that published a comprehensive whole-genome breast cancer study in Nature (2025) analyzing 1,364 genomes and clinical data; identified biomarkers linked to treatment responses and prognosis supporting precision oncology.
  • Seoul St. Mary's HospitalcoreStrategic or Co-development Partner · 3 December 2025Research consortium partner with Inocras and Samsung Medical Center on the Nature (2025) whole-genome breast cancer study of 1,364 genomes with clinical records.
  • Ultima GenomicscoreTechnology or IntegrationTechnology integration partner: Inocras's MRDVision platform merges its CancerVision whole-genome platform with Ultima Genomics' ppmSeq™ technology to achieve parts-per-million level ctDNA sensitivity. Ultima UG 100 sequencing is also used in Inocras's research sequencing services. Featured as a partner logo on the Inocras website.
  • Samsung Life InsurancecoreStrategic or Co-development PartnerListed as a partner on Inocras's website; relationship provides commercial channel for whole-genome insights into insurance / health offerings.
  • Asan Medical CentercoreStrategic or Co-development PartnerListed as a partner on the Inocras website; academic medical center collaboration supporting clinical research and validation.
  • DNAVisitminorChannel Partner/ Reseller/ DistributorListed as a partner on the Inocras website; consumer/channel partner enabling patient access to Inocras's whole-genome tests.
  • Guide GeneticsminorStrategic or Co-development PartnerListed as a partner on the Inocras website; collaboration supporting genetic testing / counseling access.
  • Seoul Clinical Laboratories (SCL)coreStrategic or Co-development PartnerListed as both an investor and partner on the Inocras website; Korean clinical laboratory collaboration supporting sample handling and clinical reach.
  • Massive BiominorGTM or Marketing PartnerListed as a partner on the Inocras website; GTM partner supporting clinical trial enrollment and patient matching services.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Inocras competitors and assessment

Company assessment

Direct peers

  • Tempus AI: AI-driven precision medicine company offering multi-modal molecular profiling (DNA/RNA), MRD, and biopharma data services. Directly competes with Inocras in AI-led oncology genomics and clinical-trial enablement.
  • Guardant Health: Liquid biopsy leader with Guardant360 (tumor profiling) and Reveal MRD. Direct competitor in oncology ctDNA profiling and MRD, where Inocras positions MRDVision with whole-genome panel-free sensitivity.
  • Natera: Oncology and reproductive health testing company whose Signatera tumor-informed MRD is the entrenched standard. Overlaps directly with Inocras's MRDVision in MRD use cases across solid tumors.
  • Caris Life Sciences: Molecular profiling company offering MI Profile (tumor WES/WTS) and Caris Assure MRD. Closely comparable WGS/WES-based profiling and biopharma services model targeting similar oncologists and pharma customers.
  • Personalis: Cancer genomics company with NeXT Personal (tumor-informed, whole-genome MRD) and ImmunoID Next platform. Most direct peer to Inocras's WGS-based tumor profiling and MRD strategy.

Broad incumbents

  • Foundation Medicine: Roche subsidiary and pioneer of comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx). Competes head-to-head in solid-tumor profiling with an FDA-approved panel; broader portfolio and deeper payer coverage than Inocras.
  • NeoGenomics: Clinical oncology and rare-disease laboratory offering comprehensive tumor profiling and heme malignancies panels. Competes in the hospital/community oncology channel with broader test menus.
  • Veracyte: Molecular diagnostics company with oncology (Decipher Prostate, Afirma) and recently expanded MRD/biomarker offerings. Overlaps with Inocras in genomic-based clinical decision support for oncologists.
  • Exact Sciences (Genomic Health): Oncology diagnostics leader with Oncotype DX and an emerging MRD franchise (Oncodetect). Comparable in bringing multi-gene and emerging tumor-informed testing into community oncology practice.

Emerging players

  • Strand Life Sciences: Bioinformatics and genomics services company serving hospitals, clinicians, and researchers in India and globally. Comparable as a bioinformatics-led, hospital-anchored clinical genomics provider; partial overlap in clinical reporting and rare-disease use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Inocras social profiles

Digital presence

Inocras compliance and trust

Trust signal

Compliance6 records

Inocras financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inocras leadership team

Management profile

Number of profiles

Profiles9 records

Inocras subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Inocras funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inocras M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inocras

What does Inocras do?

Inocras delivers CAP/CLIA-certified whole-genome sequencing clinical diagnostic tests—CancerVision for solid tumor profiling, MRDVision for minimal residual disease detection, and RareVision for rare disease diagnosis—processed in its own San Diego laboratory with a 2-week turnaround. It also offers end-to-end research sequencing and bioinformatics services (WGS, WES, WTS, methylation, single-cell, spatial) and biopharma clinical trial support, all built on a cloud-native AWS HealthOmics platform and proprietary AI including the DNAChunker architecture and Cancer Foundation Model.

Is Inocras a public or private company?

Inocras is a private company. It is classified as venture growth investor backed and is currently operating.

When was Inocras founded?

Inocras was founded in 2020. It employs 51 to 100 people.

Where is Inocras based?

Inocras is headquartered in San Diego, United States, in the North America region.

How does Inocras make money?

Four revenue lines are on record. Clinical Genomic Testing Services (CancerVision, MRDVision, RareVision) is the primary driver. The others are research Sequencing & Bioinformatics Services, biopharma Partnership / Clinical Trial Support and MRDVision Follow-up Testing (Recurring).

Who are Inocras's main competitors?

Direct peers on record are Tempus AI, Guardant Health, Natera, Caris Life Sciences and Personalis. Broad incumbents are Foundation Medicine, NeoGenomics, Veracyte and Exact Sciences (Genomic Health). Strand Life Sciences is listed as an emerging player.

Does Inocras have an API?

No public API is recorded for Inocras.

What industry is Inocras in?

Inocras's product category is Clinical Genomic Diagnostics. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogM42 and Inocras Announce Strategic Collaboration to Advance Earlier Detection of Cancer Recurrence in the UAE Using Whole Genome Powered MRD TechnologyM42 and Inocras announced a collaboration to deploy Inocras' MRDVision whole-genome MRD platform in the UAE, starting with a breast cancer pilot at Cleveland Clinic Abu Dhabi. The pilot targets higher-risk breast cancers, aiming to generate local evidence for integrating MRD testing into UAE breast cancer care.FinancialContent Business PageM42 and Inocras Announce Strategic Collaboration to Advance Earlier Detection of Cancer Recurrence in the UAE Using Whole Genome Powered MRD TechnologyM42 and Inocras announced a collaboration to deploy Inocras' MRDVision whole-genome MRD testing in the UAE, starting with a breast cancer pilot at Cleveland Clinic Abu Dhabi. The pilot targets high-risk breast cancers, aiming to generate local evidence for integrating MRD testing into UAE breast cancer care.Startup ResearcherInocras and M42 Partner to Launch MRDVision Blood Test in UAEInocras and M42 announced a partnership to bring MRDVision, a minimal residual disease blood test, to the UAE. The pilot will target high-risk breast cancer patients at Cleveland Clinic Abu Dhabi, with M42 planning to perform the test in its own UAE laboratories. The collaboration aims to establish cancer monitoring as a sustainable service in the UAE.NaverU.S. cancer genomics firm Inocras clears key hurdle for Kosdaq listingInocras received A grades from two designated evaluation agencies, meeting requirements for a Kosdaq listing. The company plans to file for a preliminary listing review with the Korea Exchange soon, using Korean Depositary Receipts backed by its U.S. entity.MkU.S. cancer genomics firm Inocras clears key hurdle for Kosdaq listingInocras Inc. passed the technology assessment for a special-track listing on South Korea's Kosdaq, receiving A grades from two evaluation agencies. The assessment took about three months after the company applied in late July. It is expected to file for a preliminary listing review with the Korea Exchange soon.San Diego Business JournalInocras Focused on Domestic ExpansionInocras, a whole-genome sequencing company, closed a $31 million Series B-3 round to expand in the U.S., targeting 10+ academic medical centers. It seeks Medicare reimbursement for its CancerVision platform by 2026-2027, with MRDVision following. The company aims to analyze one million cancer biopsies.Wowtale[Korean Startup Weekly News #130] Healthtech goes GlobalKorean healthtech startups dominated the weekly funding landscape, led by Inocras securing $31 million in Series B-3 financing to expand its cancer diagnostics platform into U.S. hospitals. This global expansion trend was mirrored by other firms such as Mediqstar and Woori Technology raising capital for international growth in diagnostics and energy sectors respectively.VC News DailyInocras Closes $31M in Oversubscribed Series B-3Inocras raised $31 million in an oversubscribed Series B-3 financing round held in San Diego, California. The round involved participation from various new and existing financial and strategic investors, including NDS Corporation and Aimed Bio Inc.StartuptodayInnocras surpasses 100 million dollars in cumulative investment... Full-scale entry into the U.S. market for precision diagnosis of whole genome cancer.Innoclass completed a $31 million Series B-3 round, bringing cumulative investment to $100 million. The company will use the funds to expand its whole-genome cancer diagnostics into U.S. hospitals, building on its platform used by over 100 Asian institutions. It aims to establish its solutions as standards in U.S. cancer treatment.VenturesquareDunamu & Partners invests in the cancer genome company InnoCras for the fourth time... a total of 14.5 billion bet.Dunamu & Partners made a fourth investment in cancer genomics firm Innocras, raising $31 million (about 45.1 billion won). The cumulative investment reached 14.5 billion won, and the company plans to expand its U.S. hospital market presence.